Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)

NCT04601051 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
Wild-Type Transthyretin Cardiac Amyloidosis

Interventions

BIOLOGICAL: NTLA-2001

Sponsor

Intellia Therapeutics